This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
by Zacks Equity Research
Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.
CGENPositive Net Change XENEPositive Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates
by Zacks Equity Research
Mesoblast (MESO) skyrockets 208.2% year to date on encouraging progress with its pipeline candidates.
NVSPositive Net Change INCYNegative Net Change MESOPositive Net Change ALXOPositive Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
4 Best-Performing Sector ETFs of June
by Sweta Killa
We have highlighted four top-performing ETFs from different sectors that have led the way in June.
AMLPPositive Net Change BBPPositive Net Change MAGSPositive Net Change WGMIPositive Net Change
biotechs bitcoin etfs fang
CHMP Endorses Moderna's (MRNA) mRNA-based RSV Vaccine
by Zacks Equity Research
If approved, the RSV vaccine will be Moderna's (MRNA) second approved product in the European Union.
GSKPositive Net Change PFEPositive Net Change MRNAPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
by Zacks Equity Research
Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
CGENPositive Net Change HRTXPositive Net Change RCKTNegative Net Change ARQTPositive Net Change
biotechs gene-therapy medical
Regeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
by Zacks Equity Research
Regeneron (REGN) gets positive CHMP recommendation for odronextamab for the treatment of adults with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.
REGNNegative Net Change SNYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs pharmaceuticals
Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug
by Zacks Equity Research
Apellis (APLS) declines as CHMP issues a second negative opinion for the approval of intravitreal pegcetacoplan to treat GA in the EU. The company plans to seek re-examination of the same.
CGENPositive Net Change APLSPositive Net Change ANVSNegative Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug
by Zacks Equity Research
PTC Therapeutics (PTCT) falls as the EC's advisory committee adopts a negative opinion regarding the renewal of the conditional marketing approval of Translarna to treat nmDMD in the EU.
CGENPositive Net Change PTCTPositive Net Change ANVSNegative Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
CDC Narrows Age Recommendation for Use of RSV Vaccine
by Zacks Equity Research
The U.S. CDC recommends that adults aged 75 years and above get an RSV shot. Those aged 60 to 74 years should only get the shot if they are at high risk for severe RSV due to chronic conditions.
GSKPositive Net Change PFEPositive Net Change MRNAPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod
by Zacks Equity Research
Pfizer (PFE) and BioNTech's Omicron JN.1-adapted COVID-19 vaccine gets the Committee for Medicinal Products for Human Use's positive opinion recommending marketing authorization.
PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change
biotechs pharmaceuticals
Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting
by Zacks Equity Research
Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.
CGENPositive Net Change COGTPositive Net Change ANVSNegative Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Denali (DNLI) Outperforms Industry in 3 Months: Here's Why
by Zacks Equity Research
Denali (DNLI) gains 11.9% in three months on positive updates on its candidates.
SNYPositive Net Change BIIBPositive Net Change DNLIPositive Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote
by Zacks Equity Research
Merck's (MRK) vaccine, Capvaxive, gets unanimous recommendation by a CDC committee for adults aged 65 years and older for pneumococcal vaccination and those with certain other underlying conditions.
MRKPositive Net Change CGENPositive Net Change ANVSNegative Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals vaccines
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) and Alimera Sciences, Inc. (ALIM) are in the spotlight following study and merger updates, respectively.
ALNYNegative Net Change ALIMPositive Net Change JAZZPositive Net Change SRPTPositive Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals
Moderna (MRNA) Shares Decline on RSV Vaccine Efficacy Data
by Zacks Equity Research
Moderna (MRNA) stock sinks after new data shows the efficacy of its mRNA-based RSV vaccine fell sharply in the second year and was lower than that of rival vaccines marketed by GSK and Pfizer.
GSKPositive Net Change PFEPositive Net Change MRNAPositive Net Change
biotechs medical messenger-rna vaccines
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma
by Zacks Equity Research
Following the label expansion, AbbVie's (ABBV) Epkinly is the first bispecific antibody approved to treat relapsed/refractory (R/R) follicular lymphoma and R/R diffuse large B-cell lymphoma.
ABBVPositive Net Change HRTXPositive Net Change GMABPositive Net Change ARQTPositive Net Change
biotechs medical pharmaceuticals
Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down
by Zacks Equity Research
Intellia (NTLA) appoints Edward Dulac as its new chief financial officer after Glenn Goddard steps down from his role with effect from Jun 30.
REGNNegative Net Change NTLAPositive Net Change RAPTPositive Net Change ALGSPositive Net Change
biotechs
Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study
by Zacks Equity Research
Beam Therapeutics (BEAM) doses the first patient in a phase I/II study, evaluating in vivo base editor BEAM-302 for treating alpha-1 antitrypsin deficiency.
BEAMPositive Net Change RAPTPositive Net Change ALGSPositive Net Change ACRVPositive Net Change
biotechs
Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug
by Zacks Equity Research
Dr. Reddy's (RDY) is set to acquire Haleon's leading global NRT brand, Nicotinell, and its related portfolio across all formats of the drug for GBP 500 million to boost its OTC presence worldwide.
RDYPositive Net Change ANVSNegative Net Change ALXOPositive Net Change HLNPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal
by Zacks Equity Research
Novo Nordisk (NVO) declines as a late-stage study of its uncontrolled hypertension and advanced chronic kidney disease candidate, ocedurenone, fails to achieve the primary goal.
NVOPositive Net Change CGENPositive Net Change ANVSNegative Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business
by Zacks Equity Research
CASI Pharmaceuticals (CASI) gets a proposal letter from its chairman for acquiring its business operations in China. Its shares rise on the news.
CGENPositive Net Change CASINegative Net Change ANVSNegative Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bayer's (BAYRY) AskBio Advances Parkinson Disease Study
by Zacks Equity Research
Bayer's (BAYRY) wholly owned and independently operating subsidiary AskBio started recruitment in the phase II study for Parkinson's disease.
BAYRYPositive Net Change CGENPositive Net Change ANVSNegative Net Change ALXOPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
by Zacks Equity Research
Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.
AZNPositive Net Change TBPHPositive Net Change HRTXPositive Net Change ARQTPositive Net Change
biotechs medical pharmaceuticals
Do Options Traders Know Something About Amicus (FOLD) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Amicus (FOLD) stock based on the movements in the options market lately.
FOLDPositive Net Change
biotechnology biotechs medical
ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why
by Zacks Equity Research
ImmunityBio (IBRX) rises 17% in the past week as it announces insurance coverage as well as the treatment of the first patients with its newly approved bladder cancer immunotherapy, Anktiva.
CGENPositive Net Change ANVSNegative Net Change ALXOPositive Net Change IBRXPositive Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals